House Dust Mite Disease Epidemiology Forecast 2026-2035

House dust mite disease is a major contributor to allergic respiratory disorders worldwide. According to Huey-Jy Huang et al., 2023, house dust mite allergy affects approximately 65-130 million people globally. As per Ki Lam et al., 2025, more than 260 million individuals are diagnosed with asthma worldwide, causing at least 359,000 deaths annually, while allergic rhinitis impacts 16-25% of the populations in developed countries. According to the house dust mite disease epidemiology forecast, the patient pool is projected to expand steadily due to rising urbanization and allergen exposure.

House Dust Mite Disease Epidemiology Forecast Report Coverage

The analyst's “House Dust Mite Disease Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of house dust mite disease. It projects the future incidence and prevalence rates of house dust mite disease cases across various populations. The study covers age, gender, and type as major determinants of the house dust mite disease population. The report highlights patterns in the prevalence of house dust mite disease over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of house dust mite disease in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

House Dust Mite Disease Understanding: Disease Overview

House dust mite disease refers to allergic conditions triggered by exposure to house dust mites, primarily Dermatophagoides pteronyssinus and Dermatophagoides farinae. These microscopic arthropods thrive in warm, humid indoor environments and are commonly found in bedding, carpets, and upholstered furniture. The disease occurs when susceptible individuals develop immunoglobulin E (IgE)-mediated hypersensitivity reactions to mite allergens present in their fecal particles and body fragments. Clinical manifestations include allergic rhinitis, allergic asthma, and atopic dermatitis. The condition is broadly classified into respiratory and cutaneous allergic conditions, depending on the primary organ system involved.

House Dust Mite Disease Epidemiology Perspective

The house dust mite disease epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for house dust mite disease epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for house dust mite disease and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Samia T. Al-Shouli et al., 2025, house dust mite allergy affects approximately 65-130 million individuals worldwide. Higher indoor allergen concentrations are associated with older single-family homes, absence of resident children, and bedroom humidity above 70%, particularly in temperate climatic conditions.
• As per Bhaveshkumar Manilal Patel et al., 2024, sensitization patterns differ by species and gender. Females demonstrate higher prevalence than males, with Dermatophagoides pteronyssinus identified in 72.5%, Dermatophagoides farinae in 66.25%, and Blomia tropicalis in 61.25% of cases.
• According to Vasileiado S., age-specific trends show cumulative allergic rhinitis incidence reaching 33.6% by 19 years. Prevalence increases from 15.6% at age 8 to 37.7% at 19, with higher incidence in girls and greater remission rates among boys.
• As per Schiffers C. et al., 2023, current asthma prevalence stands at 4.4% overall, peaking at 5.3% in individuals aged 40-49 years. Ever-asthma prevalence is 7.9% and declines significantly beyond 60 years of age.
• According to Kaitlyn R. Chan BA et al., 2026, atopic dermatitis prevalence is consistently higher in children than adults, rising from 10.7% to 12.7% in children between 2021 and 2024, while adult prevalence shows minimal and statistically non-significant change.

Country-wise House Dust Mite Disease Epidemiology

The house dust mite disease epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In United States, allergic conditions associated with house dust mite exposure remain a significant public health concern. Data from the U.S. Centers for Disease Control and Prevention indicate that approximately 31.8% of adults in the country have at least one allergic condition, including respiratory allergies frequently triggered by indoor allergens such as dust mites. House dust mite allergy alone affects nearly 20 million individuals nationwide. In Germany, allergic diseases such as allergic rhinitis affect roughly 25% of the population, with house dust mites recognized as one of the most common indoor allergens contributing to respiratory allergic disorders. These figures highlight the substantial burden of dust mite-related allergic diseases across developed regions.

House Dust Mite Disease: Treatment Overview

Treatment of house dust mite disease focuses on allergen avoidance, pharmacotherapy, and immunotherapy. Environmental control measures, such as using allergen-proof mattress covers, reducing indoor humidity, and frequent washing of bedding in hot water, are essential. Pharmacological management includes antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, and inhaled corticosteroids for asthma control. In moderate to severe cases, allergen-specific immunotherapy, administered subcutaneously or sublingually, is recommended to modify the immune response and reduce long-term symptom severity. Patient education and regular monitoring are critical for effective disease management.

Key Questions Answered

• What are the key findings of house dust mite disease epidemiology in the 8 major markets?
• What will be the total number of patients with house dust mite disease across the 8 major markets during the forecast period?
• What was the country-wise house dust mite disease epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of house dust mite disease patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of house dust mite disease during the forecast period of 2026-2035?
• What are the currently available treatments for house dust mite disease?
• What are the disease risks, signs, symptoms, and unmet needs of house dust mite disease?

Scope of the House Dust Mite Disease Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of house dust mite disease based on several factors.
• House Dust Mite Disease Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The house dust mite disease report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.